|
1. |
Editorial |
|
Journal of Dermatological Treatment,
Volume 3,
Issue 3,
1992,
Page 113-113
Preview
|
PDF (113KB)
|
|
ISSN:0954-6634
DOI:10.3109/09546639209088702
出版商:Taylor&Francis
年代:1992
数据来源: Taylor
|
2. |
Fluconazole in the treatment of onychomycosis caused by dermatophytes |
|
Journal of Dermatological Treatment,
Volume 3,
Issue 3,
1992,
Page 115-117
KuokkanenK,
AlavaS,
Preview
|
PDF (247KB)
|
|
摘要:
The present investigation is an appraisal of fluconazole in the treatment of onychomycosis caused by dermatophytes. The response to fluconazole of onychomycosis caused byTrickopkyton rubrumwas evaluated in the 46 most severely affected nails of 20 patients. The mean duration of fluconazole therapy was 9.3 months and the dose was 150 mg once a week. All fingernails and 92% of toenails were clinically and mycologically free of infection at the end of treatment. After 6 months follow-up the cure rate in toenails was 83% and in fingernails still 100%. No significant abnormalities were noted in laboratory test results. This study suggests that fluconazole is effective in the long-term therapy of onychornycosis.
ISSN:0954-6634
DOI:10.3109/09546639209088703
出版商:Taylor&Francis
年代:1992
数据来源: Taylor
|
3. |
Treatment of dandruff with a ketoconazole 2% shampoo |
|
Journal of Dermatological Treatment,
Volume 3,
Issue 3,
1992,
Page 119-123
PiepponenT,
SuhonenR,
RantanenT,
BlomqvistK,
PajarreR,
LehtonenL,
Preview
|
PDF (398KB)
|
|
摘要:
In the present trial, 101 patients with a clinical diagnosis of dandruff or seborrhoeic dermatitis with desquamation (dandruff) were treated with ketoconazole shampoo or hydrocortisone liniment in a double-blind (doubledummy) fashion. Significant reductions from baseline symptom severity (P<0.05) were seen in both treatment groups for desquamation, pruritis and erythema. There were no significant differences between the treatment groups at the endpoint. The proportion of patients who responded to the treatment, i.e. who were rated as normalized or markedly improved, was slightly higher in the ketoconazole group as judged by both investigator assessment (88% in ketoconazole vs. 80% in hydrocortisone group) and patient assessment (86% in ketoconazole vs. 82% in hydrocortisone group). Similarly, the percentage of normalized patients was higher in the ketoconazole group compared with the hydrocortisone group. The difference reached a statistically significant level (P= 0.011) in patient assessment. Seven of the 51 (13.7%) ketoconazole patients reported adverse events compared with 6 of the 50 (12%) hydrocortisone patients. All but one of the adverse events were dermatological or cosmetic in nature. It is obvious that the double-dummy design caused additional adverse events for ketoconazole patients, since the placebo liniment contained propylene glycol and isopropyl alcohol, which are known to cause skin irritation. Two ketoconazole patients discontinued the treatment due to irritation. Two hydrocortisone patients discontinued only the liniment treatment, one due to irritation and one due to itching. In conclusion, ketoconazole 2% shampoo is at least as effective as hydrocortisone 1% liniment in the treatment of dandruff. Ketoconazole shampoo may normalize the dandruff condition more often than hydrocortisone liniment does. Both treatments were well tolerated.
ISSN:0954-6634
DOI:10.3109/09546639209088704
出版商:Taylor&Francis
年代:1992
数据来源: Taylor
|
4. |
Mometasone furoate cream 0.1% vs. hydrocortisone cream 1% in the treatment of seborrhoeic dermatitis |
|
Journal of Dermatological Treatment,
Volume 3,
Issue 3,
1992,
Page 125-128
MedanskyRs,
LepawMI,
ShavinJS,
ZimmermanEH,
JonesML,
PeetsEA,
SamsonC,
TaylorE,
Preview
|
PDF (430KB)
|
|
摘要:
The safety and efficacy of mometasone furoate cream 0.1% (applied once daily), and hydrocortisone cream 1% (applied twice. daily) were compared in a 6-week multicentre, randomized, third-party-blind, trial in 117 seborrhoeic dermatitis patients. Most patients were cleared of disease signs and symptoms during the first 3 weeks of treatment. The mometasone-treated patients showed a 93% improvement in disease sign/symptom scores vs. 85% improvement among hydrocortisone-treated patients (P<0.05). Transient signs of skin atrophy were observed after the third week of treatment, which was beyond the period of the drug's therapeutic effect.
ISSN:0954-6634
DOI:10.3109/09546639209088705
出版商:Taylor&Francis
年代:1992
数据来源: Taylor
|
5. |
Bioavailability of two 8-methoxypsoralen formulations |
|
Journal of Dermatological Treatment,
Volume 3,
Issue 3,
1992,
Page 129-132
BeaniJC,
BonnotD,
BerthodF,
BoitardM,
ReymondJL,
BerielH,
AmblardP,
Preview
|
PDF (272KB)
|
|
摘要:
The aim of the study was to compare the pharmacokinetics of two formulations of 8-methoxypsoralen: a commercial tablet formulation (B) and capsules containing 8-MOP dissolved in a mixture of polyethylene glycol and glycerol (A). The pharmacokinetic parameters studied were the time and value of the maximum peak concentration of 8-MOP (TmaxandCmax) and the area under the curve (AUC) of concentration versus time. The main results were: an earlier peak plasma concentration for A (30 min versus 126 min); less variability in the absorption of 8-MOP and inCmaxfor A; a faster rate of elimination with A; and no significant difference between ratios of ingested dose and plasma levels reached. Thus, the more stable bioavailability of the new formulation was clearly demonstrated.
ISSN:0954-6634
DOI:10.3109/09546639209088706
出版商:Taylor&Francis
年代:1992
数据来源: Taylor
|
6. |
Management of methoxsalen-induced nausea with metoclopramide |
|
Journal of Dermatological Treatment,
Volume 3,
Issue 3,
1992,
Page 133-136
MillerR,
MurraySJ,
MurrayAH,
Preview
|
PDF (285KB)
|
|
摘要:
Nausea is a common adverse side-effect frequently encountered in patients receiving PUVA therapy. A prospective study was done in those patients whose nausea was not controlled with usual therapeutic agents or suggestions. A total of 17 patients were entered into the study and placed on metoclopramide in varying doses on the day of PUVA therapy. Nausea was assessed by means of a visual analogue scale. In all patients studied, significant benefit and control of nausea was achieved with few side-effects seen.
ISSN:0954-6634
DOI:10.3109/09546639209088707
出版商:Taylor&Francis
年代:1992
数据来源: Taylor
|
7. |
Localized acne as a complication of megavoltage radiotherapy |
|
Journal of Dermatological Treatment,
Volume 3,
Issue 3,
1992,
Page 137-138
HepburnNC,
CrellinRP,
BeveridgeGW,
RodgerA,
TidmanMJ,
Preview
|
PDF (258KB)
|
|
摘要:
Two cases in whom localized acne occurred at the site of megavoltage radiotherapy are described. In both, the eruption developed several months after treatment was completed and was restricted to the field of radiation. We review the literature and comment on the aetiology of this phenomenon.
ISSN:0954-6634
DOI:10.3109/09546639209088708
出版商:Taylor&Francis
年代:1992
数据来源: Taylor
|
8. |
Successful treatment of therapy-resistant acral psoriatic lesions with intravenous administration of Lipo PGE1 (prostaglandin E1 incorporated into lipid microspheres) |
|
Journal of Dermatological Treatment,
Volume 3,
Issue 3,
1992,
Page 139-141
AoyarnaH,
RokugoM,
TagamiH,
Preview
|
PDF (455KB)
|
|
摘要:
Remarkable improvement in psoriatic lesions involving the fingers and nails in three Japanese patients was produced by daily intravenous administration of Lipo PGE1. The lesions in other skin areas did not seem to respond well to this treatment.
ISSN:0954-6634
DOI:10.3109/09546639209088709
出版商:Taylor&Francis
年代:1992
数据来源: Taylor
|
9. |
Cytokines in dermatotherapy |
|
Journal of Dermatological Treatment,
Volume 3,
Issue 3,
1992,
Page 143-152
TrautingerF,
SchwarzT,
LugerTA,
Preview
|
PDF (1267KB)
|
|
摘要:
Cytokines are produced by almost any cell and function as important mediators of cell activation, differentiation and proliferation. As more cytokines become available several clinical trials have been performed using cytokines to treat skin diseases. The broadest clinical experience exists with the use of interferons (IFN). Treatment of condylomata acuminata with IFN as an adjuvant therapy appears to be promising. Cutaneous T-cell lymphoma may be treated successfully with IFNαin combination with retinoids and PUVA, respectively. Treatment of malignant melanoma with systemic IFN alone turned out not to be superior to other therapies. Administration of IFNαin AIDS-assoc-iated Kaposi's sarcoma resulted in regression rates of between 20% and 50%. IFNαapplied intralesionally was successful in actinic keratosis, basal and squamous cell carcinomas. Other dermatoses treated with some success with IFN include atopic dermatitis, systemic mastocytosis, lupus erythematosus, Behset's disease, keloids, granulo-matous diseases and leishmaniasis. Interleukin-2 (IL-2) was shown to be of some benefit in treatment of patients with melanoma either as a monotherapy or in conjunction with adoptive immunotherapy using concurrent transfer of either lymphokine-activated killer cells (LAK) or tumour infiltrating lymphocytes (TIL). However, toxicity related to IL-2 administration is severe. According to preliminary reports, tumour necrosis factorα(TNFα) seems to be effective in the treatment of some patients with psoriasis. Early clinical trials indicate growth factors as promising therapeutic agents to improve wound healing. Because of the ability of colony stimulating factors (CSF) to counteract the complications of chemotherapy, in particular bone marrow failure and the consequent susceptibility to infection and bleeding, a considerable number of patients, including those with malignant melanoma and AIDS, seem to be potential candidates for CSF treatment in combination with standard therapies.
ISSN:0954-6634
DOI:10.3109/09546639209088710
出版商:Taylor&Francis
年代:1992
数据来源: Taylor
|
10. |
Erythromelalgia: a personal perspective |
|
Journal of Dermatological Treatment,
Volume 3,
Issue 3,
1992,
Page 153-158
BelchJJF,
Preview
|
PDF (710KB)
|
|
摘要:
Erythromelalgia is the syndrome or group of symptoms characterized by intense burning pain and raised temperature of the affected part (usually the lower limbs), and associated with redness of the skin. It occurs in both a primary and a secondary form and treatment can be difficult. The key to understanding this disorder is in the careful evaluation of the patient, both in the clinic and in the laboratory. Both forms of erythromelalgia are discussed in this review, as are suggestions for evaluation and management of the patient.
ISSN:0954-6634
DOI:10.3109/09546639209088711
出版商:Taylor&Francis
年代:1992
数据来源: Taylor
|
|